Azitra to Execute 1-for-10 Reverse Stock Split Amid Market Challenges

  • Azitra will implement a 1-for-10 reverse stock split effective October 26, 2026, reducing shares from 60.6M to ~6.06M.
  • The split was approved by the board on October 14, 2026, following shareholder authorization in June 2026.
  • Fractional shares will be compensated with cash based on the 5-day average closing price preceding the split.
  • The company's stock will continue trading under the symbol AZTR on the NYSE American.

Reverse stock splits are often a last-resort measure for companies facing delisting threats or seeking to attract institutional investors. Azitra's move comes as it navigates the clinical-stage biopharmaceutical landscape, where capital efficiency and market positioning are critical. The company's focus on precision dermatology and cosmeceuticals may benefit from the perceived stability of a higher share price, but execution risks remain.

Market Perception
How the reverse stock split will impact investor sentiment and trading liquidity for Azitra.
Regulatory Compliance
Whether the split helps Azitra maintain its NYSE American listing requirements.
Strategic Intent
The pace at which Azitra advances its clinical-stage pipeline amid financial restructuring.